| 1 | Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment | 25.6 | 13 | Citations (PDF) |
| 2 | Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy | 13.9 | 28 | Citations (PDF) |
| 3 | Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study | 2.0 | 30 | Citations (PDF) |
| 4 | STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming | 14.1 | 24 | Citations (PDF) |
| 5 | Landscape of helper and regulatory antitumour CD4+ T cells in melanoma | 40.1 | 94 | Citations (PDF) |
| 6 | Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition | 3.7 | 26 | Citations (PDF) |
| 7 | Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice | 0.6 | 0 | Citations (PDF) |
| 8 | Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer | 0.6 | 0 | Citations (PDF) |
| 9 | HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors | 14.1 | 47 | Citations (PDF) |
| 10 | In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer | 13.1 | 89 | Citations (PDF) |
| 11 | Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses | 13.1 | 60 | Citations (PDF) |
| 12 | Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021, 9, e002092 | | 10 | Citations (PDF) |
| 13 | Evolution of delayed resistance to immunotherapy in a melanoma responder | 25.6 | 68 | Citations (PDF) |
| 14 | Abstract 387: Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response | 0.6 | 2 | Citations (PDF) |
| 15 | Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma | 40.1 | 287 | Citations (PDF) |
| 16 | Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy | 6.4 | 97 | Citations (PDF) |
| 17 | Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance | 0.6 | 14 | Citations (PDF) |
| 18 | Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants | 7.7 | 24 | Citations (PDF) |
| 19 | Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma | 14.1 | 23 | Citations (PDF) |
| 20 | Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade | 2.1 | 23 | Citations (PDF) |
| 21 | Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome | 11.3 | 46 | Citations (PDF) |
| 22 | Reversal of pre-existing NGFR-driven tumor and immune therapy resistance | 14.1 | 65 | Citations (PDF) |
| 23 | Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma | 6.4 | 26 | Citations (PDF) |
| 24 | Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring | 25.6 | 237 | Citations (PDF) |
| 25 | SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth | 2.9 | 13 | Citations (PDF) |
| 26 | Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2 | 26.4 | 91 | Citations (PDF) |
| 27 | Targeting the cyclin-dependent kinase 5 in metastatic melanoma | 7.7 | 17 | Citations (PDF) |
| 28 | Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era | 1.7 | 11 | Citations (PDF) |
| 29 | A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors | 6.4 | 83 | Citations (PDF) |
| 30 | Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation | 6.4 | 36 | Citations (PDF) |
| 31 | Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy | 22.7 | 444 | Citations (PDF) |
| 32 | Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition | 4.7 | 39 | Citations (PDF) |
| 33 | Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice | 14.1 | 111 | Citations (PDF) |
| 34 | ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma | 26.4 | 71 | Citations (PDF) |
| 35 | Co‐targeting
<scp>BET</scp>
and
<scp>MEK</scp>
as salvage therapy for
<scp>MAPK</scp>
and checkpoint inhibitor‐resistant melanoma | 7.2 | 71 | Citations (PDF) |
| 36 | A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma | 5.6 | 22 | Citations (PDF) |
| 37 | Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma | 6.4 | 32 | Citations (PDF) |
| 38 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018, 175, 984-997.e24 | 35.1 | 854 | Citations (PDF) |
| 39 | Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018, 175, 998-1013.e20 | 35.1 | 1,253 | Citations (PDF) |
| 40 | Toward Minimal Residual Disease-Directed Therapy in MelanomaCell, 2018, 174, 843-855.e19 | 35.1 | 456 | Citations (PDF) |
| 41 | Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma | 25.6 | 474 | Citations (PDF) |
| 42 | Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations | 6.4 | 8 | Citations (PDF) |
| 43 | An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition | 8.1 | 73 | Citations (PDF) |
| 44 | Resistance to checkpoint blockade therapy through inactivation of antigen presentation | 14.1 | 686 | Citations (PDF) |
| 45 | PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas | 40.1 | 135 | Citations (PDF) |
| 46 | Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure | 7.2 | 59 | Citations (PDF) |
| 47 | Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence | 6.4 | 73 | Citations (PDF) |
| 48 | Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines | 6.4 | 59 | Citations (PDF) |
| 49 | A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma | 6.4 | 104 | Citations (PDF) |
| 50 | sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance | 40.1 | 298 | Citations (PDF) |
| 51 | Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq | 38.2 | 2,949 | Citations (PDF) |
| 52 | Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | 3.7 | 399 | Citations (PDF) |
| 53 | Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma | 25.6 | 62 | Citations (PDF) |
| 54 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy | 14.1 | 419 | Citations (PDF) |
| 55 | Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance | 26.4 | 140 | Citations (PDF) |
| 56 | Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy | 33.4 | 190 | Citations (PDF) |
| 57 | Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma | 5.6 | 51 | Citations (PDF) |
| 58 | Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR | 25.6 | 95 | Citations (PDF) |
| 59 | Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation | 6.4 | 53 | Citations (PDF) |
| 60 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies | 16.3 | 431 | Citations (PDF) |
| 61 | EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma | 26.4 | 102 | Citations (PDF) |
| 62 | Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients | 1.3 | 14 | Citations (PDF) |
| 63 | MITF Modulates Therapeutic Resistance through EGFR Signaling | 0.7 | 70 | Citations (PDF) |
| 64 | BAP1 Has a Survival Role in Cutaneous Melanoma | 0.7 | 31 | Citations (PDF) |
| 65 | Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment | 2.5 | 31 | Citations (PDF) |
| 66 | One Hippo and many masters: differential regulation of the Hippo pathway in cancer | 4.2 | 10 | Citations (PDF) |
| 67 | Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma | 0.6 | 160 | Citations (PDF) |
| 68 | The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα | 26.4 | 175 | Citations (PDF) |
| 69 | Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics | 2.5 | 37 | Citations (PDF) |
| 70 | A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors | 26.4 | 404 | Citations (PDF) |
| 71 | BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma | 6.4 | 772 | Citations (PDF) |
